PhoenixBio Co.,Ltd. (6190) Cash flow
Market cap
¥1.5B
P/E ratio
19.6x
Phoenix Bio provides pharmaceutical testing services using PXB mice with human liver cells to help drug companies predict how medicines work in people.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Depreciation & amortization | 22 | 22 | 25 | 24 | 30 | 53 | 55 | 86 | 24 | 25 | 28 | 34 |
| Cash from operations | -8 | 259 | 45 | -187 | -160 | -13 | -102 | 16 | 277 | -79 | -73 | 69 |
| Capital expenditures | -8 | -18 | -10 | -5 | -64 | -31 | -181 | -7 | -7 | -32 | -21 | -12 |
| Cash from investing | 6 | -137 | 99 | -452 | -65 | -16 | -185 | -7 | -156 | 115 | -28 | -14 |
| Repurchases of common stock | - | - | - | - | - | -0 | - | - | - | - | - | - |
| Proceeds from issuance of term debt, net | 100 | - | 208 | - | - | - | - | - | - | 400 | - | - |
| Repayments of term debt | -50 | -53 | -184 | -56 | -56 | -26 | -20 | -2 | - | -20 | -80 | -80 |
| Cash from financing | 46 | 735 | 20 | -63 | -65 | 1,146 | -160 | -35 | 87 | -245 | -128 | -88 |